Long term outcomes and risk factors for chemotherapy induced peripheral neuropathy in childhood cancer survivors (s46.006)

Conclusions:CIPN produces significant long term morbidity in CCS. Clinical and neurophysiological abnormalities in CCS are consistent with global axonal loss, which in conjunction with altered functional axonal properties may predispose to age related degenerative change. Exposure to platinum or dual neurotoxic chemotherapy are risk factors for long term neuropathy. Relative preservation of clinical function suggests a window of opportunity for physical therapy which may preserve long term function.Study Supported by:This work was supported by the National Health and Medical Research Council (APP1114801), the Royal Australasian College of Physicians and the Cancer Institute of the New South Wales (grant number 14/TPG/1-05).Disclosure: Dr. Kandula has nothing to disclose. Dr. Farrar has nothing to disclose. Dr. Kiernan has received personal compensation in an editorial capacity for Journal of Neurology, Neurosurgery and Psychiatry. Dr. Mizrahi has nothing to disclose. Dr. Carey has nothing to disclose. Dr. Krishnan has received personal compensation for activities with Biogen Idec as a member of an advisory board. Dr. Cohn has nothing to disclose. Dr. Park has nothing to disclose.
Source: Neurology - Category: Neurology Authors: Tags: Child Neurology: Molecular Biology to Clinical Trials Source Type: research